Download PDF
Open Access
CC BY 4.0 · Indian J Med Paediatr Oncol 2025; 46(03): 321-326
DOI: 10.1055/s-0042-1743508
Brief Communication

Outcomes of Allogeneic Stem Cell Transplant in Chronic Myeloid Leukemia-Blast Phase: A Single-Center Experience from South India

Authors

  • Thejeswar Nakka 

    1   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India

  • Arnab Bhattacherjee

    1   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India

  • Narendran Krishnamoorthi

    1   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India

  • Divya Bala Tumathy

    1   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India

  • Sindhu Dahagama

    1   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India

  • Biswajit Dubashi 

    1   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India

  • Prasanth Ganesan 

    1   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India

  • Smita Kayal 

    1   Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India

Funding None.
Further Information
Also available at
  Permissions and Reprints

Abstract

The blast phase (BP) is challenging to treat and leads to inferior survival in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplant (AlloSCT) is the only curative option for CML-BP. We are sharing our experience of AlloSCT in seven patients with CML-BP who underwent transplants during the period from January 2017 to December 2019. Three patients each had myeloid-BP, lymphoid-BP, and one patient had mixed phenotypic BP. Donors were matched siblings in four, mismatched siblings in one, and haploidentical in two. All patients received peripheral blood stem cell grafts. The median CD34+ dose was 7.6 (range: 6.6–8.9) × 106 cells/kg. Neutrophil engraftment was observed at a median of 15 (10–20) days and platelet engraftment at 19 days (10–22). At a median follow-up of 24 months, the 2-year leukemia-free survival (LFS) and overall survival (OS) were 43% and 57%, respectively. Transplant-related, non-relapse mortality was observed in three patients. AlloSCT results in promising survival for carefully selected patients of CML-BP, especially with a matched sibling donor.

Keywords

chronic myeloid leukemia blast phase - allogeneic hematopoietic stem cell transplant - survival

* These authors contributed equally to this work.


Ethics Approval

Institute Ethics Committee approval was taken before the commencement of the study.


Patient Consent

Waiver of consent was granted for the retrospective data and analysis.


Author's Contributions

Study conceptualization and methodology: TN, AB, SK, BD, and PG. Data collection and analysis: TN, AB, NK, SD, DBT, and SK. Manuscript writing: TN, AB, SK, NK, DBT, and BD. Review and editing: SK, BD, SD, and PG. Final approval of manuscript: all authors.




Publication History

Article published online:
28 November 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India